Murray Stahl's CRL Position Overview
Murray Stahl (via Horizon Kinetics Asset Management LLC) currently holds 12,580 shares of Charles River Laboratories International, Inc. (CRL) worth $2.51 M, representing 0.03% of the portfolio. First purchased in 2020-Q1, this long-term strategic position has been held for 24 quarters.
Based on 13F filings, Murray Stahl has maintained a strategic position in CRL, demonstrating sustained confidence in this investment. Largest addition occurred in Q2 2021, adding 75,962 shares. Largest reduction occurred in Q4 2024, reducing 54,922 shares.
Analysis based on 13F filings available since 2013 Q2
Murray Stahl's Charles River Laboratories International (CRL) Holding Value Over Time
Track share changes against reported price movement
Quarterly Charles River Laboratories International (CRL) Trades by Murray Stahl
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | -329 | Reduce 2.55% | 12,580 | $199.48 |
| Q3 2025 | -9,351 | Reduce 42.01% | 12,909 | $156.45 |
| Q2 2025 | -12,026 | Reduce 35.08% | 22,260 | $151.73 |
| Q1 2025 | -25,554 | Reduce 42.70% | 34,286 | $150.52 |
| Q4 2024 | -54,922 | Reduce 47.86% | 59,840 | $184.60 |
| Q3 2024 | -45,619 | Reduce 28.44% | 114,762 | $196.97 |
| Q2 2024 | +1,170 | Add 0.73% | 160,381 | $206.58 |
| Q1 2024 | -23,453 | Reduce 12.84% | 159,211 | $270.95 |
| Q4 2023 | -31,571 | Reduce 14.74% | 182,664 | $236.40 |
| Q3 2023 | -18,265 | Reduce 7.86% | 214,235 | $195.98 |
| Q2 2023 | -14,468 | Reduce 5.86% | 232,500 | $210.25 |
| Q1 2023 | -13,125 | Reduce 5.05% | 246,968 | $201.82 |
| Q4 2022 | -24,296 | Reduce 8.54% | 260,093 | $217.90 |
| Q3 2022 | -14,585 | Reduce 4.88% | 284,389 | $196.80 |
| Q2 2022 | +23,735 | Add 8.62% | 298,974 | $213.97 |
| Q1 2022 | +47,933 | Add 21.09% | 275,239 | $283.97 |
| Q4 2021 | +19,514 | Add 9.39% | 227,306 | $376.78 |
| Q3 2021 | +11,038 | Add 5.61% | 207,792 | $412.67 |
| Q2 2021 | +75,962 | Add 62.89% | 196,754 | $369.92 |
| Q1 2021 | +9,074 | Add 8.12% | 120,792 | $289.83 |
| Q4 2020 | -2,889 | Reduce 2.52% | 111,718 | $249.86 |
| Q3 2020 | +654 | Add 0.57% | 114,607 | $226.45 |
| Q2 2020 | +75,262 | Add 194.52% | 113,953 | $174.35 |
| Q1 2020 | +38,691 | New Buy | 38,691 | $126.21 |
Murray Stahl's Charles River Laboratories International Investment FAQs
Murray Stahl first purchased Charles River Laboratories International, Inc. (CRL) in Q1 2020, acquiring 38,691 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Murray Stahl has held Charles River Laboratories International, Inc. (CRL) for 24 quarters since Q1 2020.
Murray Stahl's largest addition to Charles River Laboratories International, Inc. (CRL) was in Q2 2021, adding 196,754 shares worth $72.78 M.
According to the latest 13F filing for Q4 2025, Murray Stahl's firm, Horizon Kinetics Asset Management LLC, owns 12,580 shares of Charles River Laboratories International, Inc. (CRL), valued at approximately $2.51 M.
As of the Q4 2025 filing, Charles River Laboratories International, Inc. (CRL) represents approximately 0.03% of Murray Stahl's publicly disclosed stock portfolio, making it one of their key holdings.
Murray Stahl's peak holding in Charles River Laboratories International, Inc. (CRL) was 298,974 shares, as reported at the end of Q2 2022.